Verastem, Inc.
Tremor tracks 11 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- A key executive is leavingSince Oct 14, 2026+11.5
Trials
- VSTMVerastem, Inc.22Calm
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Running, no new patientsPhase 2225 patientsMain results: Nov 15, 2024 - VSTMVerastem, Inc.12Calm
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Signing up patientsPhase 2105 patientsMain results: Jun 2027 - VSTMVerastem, Inc.12Calm
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Signing up patientsPhase 2185 patientsMain results: Jun 2027 - VSTMVerastem, Inc.12Calm
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Signing up patientsPhase 3270 patientsMain results: Oct 15, 2028 - VSTMVerastem, Inc.12Calm
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Signing up patientsPhase 2150 patientsMain results: Jun 2027 - VSTMVerastem, Inc.12Calm
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Signing up patientsPhase 1/2616 patientsMain results: Dec 2028 - VSTMVerastem, Inc.12Calm
Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Not started yetPhase 22 patientsMain results: Aug 1, 2027 - VSTMVerastem, Inc.12Calm
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
FinishedPhase 1/212 patientsMain results: Jun 15, 2026 - VSTMVerastem, Inc.12Calm
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Running, no new patientsPhase 1/2153 patientsMain results: Jun 2026 - VSTMVerastem, Inc.12Calm
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
Running, no new patientsPhase 216 patientsMain results: Dec 2025 - VSTMVerastem, Inc.12Calm
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Running, no new patientsPhase 1/240 patientsMain results: Aug 31, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
Oct 14, 2026
“Paterson notified the Board of Directors (the “Board”) of the Company of his decision to retire as President and Chief Executive Officer of the Company, effective January 1, 2027 (the “Effective Date”).”
Read the filing ↗
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
8 sales (0 not pre-planned) · 0 purchases
- Paterson DanPresident and CEO · Nov 3, 2026Sold 1,299 sharesabout $12 thousand · pre-planned
- Paterson DanPresident and CEO · Oct 1, 2026Sold 44,121 sharesabout $353 thousand · pre-planned
- Calkins DanielChief Financial Officer · Oct 1, 2026Sold 2,566 sharesabout $21 thousand · pre-planned
- Calkins DanielChief Financial Officer · Sep 21, 2026Sold 55 sharesabout $424 · pre-planned
- Paterson DanPresident and CEO · Aug 3, 2026Sold 1,302 sharesabout $8 thousand · pre-planned
- Paterson DanPresident and CEO · Jun 22, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.